ArticleNutrients2018
Preventive Potential of Resveratrol in Carcinogen-Induced Rat Thyroid Tumorigenesis.
Article in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Resveratrol Downregulated PRDX4 Expression to Inhibit the Progression of Renal Cell Carcinoma via Wnt/β-Catenin Pathway.Food science & nutrition · 2025Article
- Can Compounds of Natural Origin Be Important in Chemoprevention? Anticancer Properties of Quercetin, Resveratrol, and Curcumin-A Comprehensive Review.International journal of molecular sciences · 2024Review
- Research progress of plant-derived natural products in thyroid carcinoma.Frontiers in chemistry · 2023Review
- Mediterranean Diet and Thyroid: An Interesting Alliance.Nutrients · 2022Review
- Anticancer effects of natural phytochemicals in anaplastic thyroid cancer (Review).Oncology reports · 2022Review
- Effects ofOxidative medicine and cellular longevity · 2022Article
- Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer CellsNanotheranostics · 2021Article
- Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway.Molecular therapy oncolytics · 2020Article
- STAT3 signaling statuses determine the fate of resveratrol-treated anaplastic thyroid cancer cells.Cancer biomarkers : section A of Disease markers · 2020Article
- Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases mFrontiers in pharmacology · 2020Article
- Review
- Resveratrol Reverses Retinoic Acid Resistance of Anaplastic Thyroid Cancer Cells via Demethylating CRABP2 Gene.Frontiers in endocrinology · 2019Article
- The Synergistic Effects of Resveratrol combined with Resistant Training on Exercise Performance and Physiological Adaption.Nutrients · 2018Article
- Inhibition of NF-κB Signaling Pathway by Resveratrol Improves Spinal Cord Injury.Frontiers in neuroscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer (TC) is the most common endocrine malignancy without reliable preventive agent. Resveratrol possesses in vitro anti-TC activities; while its effect(s) on thyroid tumorigenesis remains unknown. This study aims to address this issue using DEN/MNU/DHPN-induced rat carcinogenesis model. 50 male Sprague-Dawley rats were separated into four groups as Group-1 (5 rats); normally fed; Group-2 (15 rats); DEN/MNU/DHPN treatment only; Group-3 (15 rats) and -4 (15 rats); DEN/MNU/DHPN treatment; followed by resveratrol intragastric (IG) injection and intraperitoneal (IP) injection; respectively; in two-day intervals for 30 weeks. The results revealed that the average resveratrol concentration in thyroid tissues was 1.278 ± 0.419 nmol/g in IG group and 1.752 ± 0.398 nmol/g in IP group. The final body weights of Group-3 and Group-4 were lighter than that (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.